InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332
InnoCare, a leading biopharmaceutical company focusing on drug innovation for cancer and autoimmune diseases, announced the first subject dosed in clinical trial of novel TYK2 (Tyrosine…
Read More...
Read More...
